CR Bard Inc
Most Recent
Baxter Exhibits Strong 1Q16 Performance, Beat Estimates
On April 26, 2016, Baxter International (BAX) released its 1Q16 earnings. After the announcement, Baxter’s share price rose ~1% from $43.63 on April 25, 2016, due to the company’s better-than-expected 1Q16 results.
How BD-Bard Acquisition Will Strengthen International Presence
C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.
How Medtronic Is Delivering on Its Covidien Synergies
In January 2015, Medtronic (MDT) acquired Covidien for ~$43 billion in cash and MDT stock in a tax inversion deal.
A Brief Look at Dividend Aristocrats
The S&P 500 Dividend Aristocrat Index is made up of 51 S&P 500 (SPY) (SPX-INDEX) companies that have increased their dividends for 25 successive years.
Key Highlights of Varian Medical Systems’ Fiscal 2Q17 Earnings
On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.
How BDX Returns Value to Its Shareholders
BD announced a quarterly cash dividend of $0.73 per share on July 25, 2017.
Baxter’s Latest Dividend and Share Repurchase Authorization
Baxter International (BAX) announced a quarterly cash dividend of $0.13 per share on November 8, 2016.
Baxter International’s Recent Product Launches and Partnerships
Baxter International’s R&D investments were around $150 million in 2Q16, which represents a YoY (year-over-year) increase of around 1%.
Vanguard Morgan Growth Fund’s Sector Composition in YTD 2016
Information technology is by far the biggest invested sector in the Vanguard Morgan Growth Fund (VMRGX), forming over a third of the total portfolio.
Varian Medical Systems Attempts to Improve Its Performance Growth
Varian Medical Systems (VAR) raised its guidance for fiscal 2016 in the view of higher-than-expected 3Q16 results reported on July 27.
What’s BSX’s Capital Allocation Strategy Going Forward?
In August 2015, BSX acquired American Medical Systems’ male urology business for $1.6 billion in cash and milestone-based payments of $50 million.
How Is Varian Positioned in the Particle Therapy Business?
Varian Medical Systems (VAR) had gross orders value of $310 million in 2015.
Growth Strategies Driving Varian Medical Systems’ Revenue
Varian Medical Systems has ventured into the proton therapy business and has a huge product pipeline in this area. The company generated approximately $300 million through its proton therapy business in 2015.
Varian Medical Systems’ Growth Potential in Radiation Oncology
Varian Medical Systems’ next big technology innovation will be high-definition radiotherapy, which is an intelligent treatment delivery system that aims to achieve 100% radiation exposure for the tumor.
Where Does Varian Medical Systems Get Most of Its Revenue?
Varian Medical Systems’ Imaging Components segment accounts for approximately 19% of the company’s total revenue. The segment reported a revenue decline of ~10% in 2015.
A Look at C. R. Bard’s Oncology Business Segment
C. R. Bard’s (BCR) Oncology segment contributes around 27% of the total revenues of the company.
Company Overview: An Introduction to C. R. Bard
Headquartered in Murray Hill, New Jersey, C. R. Bard (BCR) is a leading medical technology company in the United States.
Why VMRGX’s Year-to-Date 2016 Has Been Lackluster
As of May 27, 2016, the Vanguard Morgan Growth Fund Investor Shares (VMRGX) had fallen by 0.7% YTD (year-to-date) in 2016.
Baxter’s 1Q16 Profitability and 2016 Guidance
Baxter International (BAX) revised its 2016 guidance as the company reported a strong 1Q16. Sales guidance for the year is updated from the 2%–3% range to approximately 3%.
Innovation Drove Baxter’s Hospital Products Sales in 1Q16
Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$1.5 billion was contributed by the company’s Hospital Products business.
Strategic Initiatives Driving Baxter’s Margin Expansion Goal
Baxter witnessed a series of changes in 2015, including a change in management, operational structure, and the establishment of a new strategic framework.
Key Regulations that Affect Medical Device Companies
The US Food and Drug Administration’s Center for Devices for Radiological Health (or USFDA/CDRH) regulates the medical device industry in the United States.
How are XLV’s Moving Averages Trending?
Out of 56 stocks in XLV’s portfolio, a total of 32 stocks were trading above their 20-day moving average.
The Biotech Sector Is in a Downward Long-Term Trend
Though most of the biotech stocks rebounded from the recent lows, the long-term trend for biotech seems to be heading downward.
